1Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
2Department of Laboratory Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
© Copyright 2018. Korean Association for the Study of Intestinal Diseases.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
FINANCIAL SUPPORT: This study was supported by Inje University research grant 2015.
CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION: Y.S.K., conceptualization; P.H.S., J.H.M., writing-original draft; D.H.W., formal analysis; Y.S.K., project administration; S.Y.J, E.J.K., K.J.L., J.L., H.S., J.S.M., writing-review and editing. All authors approved the final version of the manuscript.
Values are presented as median±SD or number (%).
aSome patients were prescribed more than 1 drug. Therefore, a total of 252 drugs was prescribed in the groups of real-time PCR positive/toxin assay positive and real-time PCR positive/toxin assay negative.
bA total of 158 underlying diseases were counted, of which some of the patients had more than 1 underlying disease in the real-time PCR positive/toxin assay positive and real-time PCR positive/toxin assay negative groups.
Values are presented as median±SD or number (%).
aSome patients were prescribed more than 1 drug. Therefore, a total of 284 drugs was prescribed in 90 patients.
bA total of 181 underlying diseases were counted in 90 patients, of which some had more than 1 underlying disease.
Values are presented as median±SD or median.
aGeneXpert®; Cepheid, Sunnyvale, CA, USA.
bVIDAS®, A/B; bioMérieux, Marcy L'Etoile, France.
cChromID™ C. difficile agar; bioMérieux.
Values are presented as median±SD or number (%).
aSome patients were prescribed more than 1 drug. Therefore, a total of 252 drugs was prescribed in the groups of real-time PCR positive/toxin assay positive and real-time PCR positive/toxin assay negative.
bA total of 158 underlying diseases were counted, of which some of the patients had more than 1 underlying disease in the real-time PCR positive/toxin assay positive and real-time PCR positive/toxin assay negative groups.
Values are presented as median±SD or number (%). aSome patients were prescribed more than 1 drug. Therefore, a total of 284 drugs was prescribed in 90 patients. bA total of 181 underlying diseases were counted in 90 patients, of which some had more than 1 underlying disease.
Values are presented as median±SD or median. aGeneXpert®; Cepheid, Sunnyvale, CA, USA. bVIDAS®, A/B; bioMérieux, Marcy L'Etoile, France. cChromID™
Values are presented as median±SD or number (%). aSome patients were prescribed more than 1 drug. Therefore, a total of 252 drugs was prescribed in the groups of real-time PCR positive/toxin assay positive and real-time PCR positive/toxin assay negative. bA total of 158 underlying diseases were counted, of which some of the patients had more than 1 underlying disease in the real-time PCR positive/toxin assay positive and real-time PCR positive/toxin assay negative groups.